tetracycline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, protein-synthesis inhibitors, tetracycline derivatives 2611 60-54-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • achromycin
  • tetracycline phosphate complex
  • tetracycline metaphosphate
  • tetracycline
  • tetracycline hydrochloride
  • tetracycline HCl
  • tetracycline phosphate
A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.
  • Molecular weight: 444.44
  • Formula: C22H24N2O8
  • CLOGP: -1.33
  • LIPINSKI: 1
  • HAC: 10
  • HDO: 6
  • TPSA: 181.62
  • ALOGS: -2.52
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g O
1 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1.70 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 58 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 74.92 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 77 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.78 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9.40 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.822 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.489 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.760 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.438 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 70.100 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 59.330 % High 1
herg hERG pIC50 4.507 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 2.009 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.126 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 70.720 % High 1
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIM1,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,PTK2,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 72
kinase-selectivity-class ACVR2B,AXL,BRAF,CDK16,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,JAK2,MAP2K6,MAP3K14,MAP3K2,MAPK12,MAPK7,MAPK8,PIM3,PRKDC,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 27
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.679 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 5.321 High 1
mh-clint Mouse hepatocyte intrinsic clearance 5.754 High 1
mppb Mouse plasma protein binding (% unbound) 64.380 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 4.603 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 68.230 % High 1
rat-kpuu-brain Rat brain Kpuu 0.008 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.462 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 87.190 % High 1
rppb Rat plasma protein binding (% unbound) 57.090 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 903.649 uM High 1

Approvals:

DateAgencyCompanyOrphan
Nov. 19, 1953 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 1957.27 20.09 991 9918 462618 90154920
Finger deformity 121.01 20.09 65 10844 32832 90584706
Hepatitis 90.41 20.09 72 10837 70667 90546871
Back injury 83.20 20.09 58 10851 46564 90570974
Incorrect product administration duration 81.93 20.09 42 10867 19280 90598258
Neck pain 74.99 20.09 80 10829 113883 90503655
Liver function test increased 73.19 20.09 69 10840 84786 90532752
Tuberculin test positive 72.00 20.09 24 10885 3701 90613837
Urticaria 64.23 20.09 126 10783 312608 90304930
Muscle tension dysphonia 57.76 20.09 12 10897 287 90617251
Peripheral venous disease 57.12 20.09 60 10849 83861 90533677
Underdose 54.54 20.09 48 10861 53969 90563569
Taste disorder 52.96 20.09 50 10859 61496 90556042
Obesity 52.33 20.09 64 10845 105443 90512095
Mobility decreased 51.41 20.09 101 10808 250633 90366905
Intentional product use issue 48.93 20.09 91 10818 216801 90400737
Blepharospasm 47.62 20.09 45 10864 55400 90562138
Inflammation 46.78 20.09 80 10829 178512 90439026
Eyelid exfoliation 45.89 20.09 10 10899 302 90617236
Dysphemia 44.67 20.09 16 10893 3054 90614484
Skin odour abnormal 44.32 20.09 14 10895 1821 90615717
Bursitis 44.12 20.09 66 10843 131588 90485950
Muscular weakness 43.26 20.09 84 10825 206582 90410956
Injury 42.27 20.09 81 10828 197268 90420270
Product label confusion 42.09 20.09 29 10880 22821 90594717
Immunisation reaction 41.22 20.09 11 10898 789 90616749
Onychomycosis 39.30 20.09 34 10875 37342 90580196
Administration site bruise 36.48 20.09 9 10900 472 90617066
Adverse reaction 35.30 20.09 29 10880 29683 90587855
Gastrooesophageal reflux disease 35.27 20.09 68 10841 166269 90451269
Wound infection 35.16 20.09 53 10856 106349 90511189
Vaccination complication 33.76 20.09 10 10899 1049 90616489
Product quality issue 31.31 20.09 43 10866 79282 90538256
Wheezing 30.91 20.09 80 10829 238000 90379538
Wound secretion 30.69 20.09 14 10895 4976 90612562
Breast cancer stage III 30.69 20.09 44 10865 84403 90533135
Lymphadenitis 29.91 20.09 13 10896 4124 90613414
Restrictive pulmonary disease 29.50 20.09 11 10898 2351 90615187
Cystitis interstitial 28.96 20.09 10 10899 1714 90615824
Wound complication 28.16 20.09 13 10896 4750 90612788
Back pain 27.60 20.09 3 10906 317172 90300366
Food intolerance 27.36 20.09 12 10897 3890 90613648
Oral pruritus 27.12 20.09 11 10898 2940 90614598
Administration site swelling 26.37 20.09 9 10900 1490 90616048
Normal newborn 26.09 20.09 22 10887 23340 90594198
Folliculitis 25.83 20.09 68 10841 204285 90413253
Facet joint syndrome 25.64 20.09 44 10865 98345 90519193
Gait inability 25.27 20.09 55 10854 146401 90471137
Hypercholesterolaemia 24.83 20.09 44 10865 100848 90516690
Onychomadesis 24.58 20.09 29 10880 45969 90571569
Subcutaneous abscess 24.02 20.09 13 10896 6653 90610885
Intracranial pressure increased 23.75 20.09 13 10896 6798 90610740
Scar 22.54 20.09 17 10892 15378 90602160
Injection site reaction 22.46 20.09 40 10869 92040 90525498
Toxicity to various agents 22.06 20.09 4 10905 287842 90329696
Urinary tract infection 21.86 20.09 5 10904 305627 90311911
Epilepsy 21.73 20.09 37 10872 82169 90535369
Nail disorder 20.33 20.09 30 10879 59037 90558501
Tooth discolouration 20.32 20.09 7 10902 1191 90616347

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 313.14 28.24 111 1010 99278 42520936
Somnambulism 37.26 28.24 10 1111 3405 42616809
Haemorrhagic infarction 30.46 28.24 6 1115 520 42619694

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 1437.83 21.52 759 10447 453331 110124762
Finger deformity 131.21 21.52 65 11141 33027 110545066
Back injury 96.45 21.52 60 11146 47339 110530754
Hepatitis 92.30 21.52 75 11131 89979 110488114
Incorrect product administration duration 89.45 21.52 43 11163 20455 110557638
Neck pain 81.33 21.52 80 11126 123050 110455043
Liver function test increased 80.89 21.52 69 11137 88479 110489614
Urticaria 78.18 21.52 126 11080 318731 110259362
Tuberculin test positive 76.42 21.52 24 11182 3644 110574449
Peripheral venous disease 69.68 21.52 62 11144 84055 110494038
Mobility decreased 68.22 21.52 101 11105 237321 110340772
Taste disorder 61.85 21.52 52 11154 65335 110512758
Intentional product use issue 59.40 21.52 97 11109 247809 110330284
Obesity 59.28 21.52 65 11141 113286 110464807
Injury 59.14 21.52 81 11125 177184 110400909
Blepharospasm 56.85 21.52 46 11160 54805 110523288
Underdose 54.93 21.52 48 11158 63506 110514587
Muscle tension dysphonia 54.14 21.52 11 11195 281 110577812
Bursitis 53.69 21.52 66 11140 129852 110448241
Wound infection 49.88 21.52 55 11151 96410 110481683
Inflammation 49.54 21.52 78 11128 193160 110384933
Folliculitis 49.10 21.52 72 11134 167581 110410512
Eyelid exfoliation 47.45 21.52 10 11196 307 110577786
Product label confusion 46.85 21.52 29 11177 22648 110555445
Administration site bruise 44.40 21.52 9 11197 227 110577866
Onychomycosis 43.53 21.52 34 11172 38497 110539596
Immunisation reaction 42.98 21.52 11 11195 798 110577295
Muscular weakness 42.54 21.52 84 11122 248384 110329709
Product quality issue 41.57 21.52 45 11161 77254 110500839
Breast cancer stage III 40.71 21.52 45 11161 79072 110499021
Gastrooesophageal reflux disease 39.84 21.52 68 11138 179908 110398185
Adverse reaction 39.83 21.52 29 11177 29565 110548528
Dysphemia 39.45 21.52 15 11191 4022 110574071
Skin odour abnormal 38.69 21.52 13 11193 2441 110575652
Wheezing 38.63 21.52 82 11124 255148 110322945
Gait inability 37.67 21.52 57 11149 136319 110441774
Hypercholesterolaemia 35.68 21.52 45 11161 90792 110487301
Administration site swelling 35.59 21.52 9 11197 622 110577471
Drug intolerance 35.57 21.52 106 11100 406406 110171687
Facet joint syndrome 33.41 21.52 45 11161 96783 110481310
Cystitis interstitial 32.19 21.52 10 11196 1464 110576629
Osteoarthritis 31.55 21.52 62 11144 182561 110395532
Bone hyperpigmentation 29.79 21.52 5 11201 42 110578051
Onychomadesis 28.88 21.52 29 11177 45634 110532459
Injection site reaction 28.62 21.52 40 11166 89030 110489063
Normal newborn 28.43 21.52 21 11185 21875 110556218
Vaccination complication 28.11 21.52 8 11198 867 110577226
Restrictive pulmonary disease 27.90 21.52 11 11195 3248 110574845
Acute kidney injury 27.64 21.52 15 11191 635415 109942678
Drug resistance 27.17 21.52 31 11175 56343 110521750
Treatment failure 26.84 21.52 75 11131 277159 110300934
Helicobacter infection 25.86 21.52 57 11149 181820 110396273
Wound secretion 25.70 21.52 13 11193 6888 110571205
Nail disorder 24.83 21.52 30 11176 57905 110520188
Oral pruritus 24.26 21.52 10 11196 3310 110574783
Blister 23.48 21.52 63 11143 227313 110350780
Coeliac disease 22.96 21.52 25 11181 43162 110534931
Epilepsy 22.34 21.52 38 11168 100171 110477922
Anaemia 22.25 21.52 14 11192 547072 110031021
Hypoaesthesia 22.05 21.52 76 11130 314147 110263946

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A01AB13 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Antiinfectives and antiseptics for local oral treatment
ATC A02BD02 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
ATC A02BD08 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
ATC D06AA04 DERMATOLOGICALS
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
ANTIBIOTICS FOR TOPICAL USE
Tetracycline and derivatives
ATC J01AA07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
TETRACYCLINES
Tetracyclines
ATC J01RA08 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC J01RA19 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC S01AA09 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antibiotics
ATC S02AA08 SENSORY ORGANS
OTOLOGICALS
ANTIINFECTIVES
Antiinfectives
ATC S03AA02 SENSORY ORGANS
OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
ANTIINFECTIVES
Antiinfectives
FDA CS M0021223 Tetracyclines
FDA EPC N0000175505 Tetracycline-class Antimicrobial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011500 Protein Synthesis Inhibitors
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35820 antiprotozoal drug
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:48001 protein synthesis inhibitor
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:76971 <em>Escherichia coli</em> metabolite
CHEBI has role CHEBI:86327 antifungal drug

Related Drugs by ATC class:

A01AB Antiinfectives and antiseptics for local oral treatment 22 drugs
amphotericin Bbenzoxonium chloridecetylpyridiniumchlorhexidinechlortetracyclineclotrimazoledomiphendoxycyclinehexetidinehydrogen peroxidemepartricinmetronidazole show all 22 →
A02BD Combinations for eradication of Helicobacter pylori 13 drugs
amoxicillinbismuth subcitrateclarithromycinesomeprazolelansoprazolelevofloxacinmetronidazoleomeprazolepantoprazolerabeprazolerifabutintinidazole show all 13 →
D06AA Tetracycline and derivatives 3 drugs
chlortetracyclinedemeclocyclineoxytetracycline
J01AA Tetracyclines 13 drugs
chlortetracyclineclomocyclinedemeclocyclinedoxycyclinelymecyclinemetacyclineminocyclineomadacyclineoxytetracyclinepenimepicyclinerolitetracyclinesarecycline show all 13 →
J01RA Combinations of antibacterials 18 drugs
amikacinazithromycincefepimecefiximecefuroximeciprofloxacinfluconazolelevofloxacinmetronidazolenitazoxanidenorfloxacinnystatin show all 18 →
S01AA Antibiotics 27 drugs
amikacinampicillinazidamfenicolazithromycinbacitracinbenzylpenicillincefmenoximecefuroximechloramphenicolchlortetracyclinedibekacindihydrostreptomycin show all 27 →
S02AA Antiinfectives 17 drugs
acetic acidaluminium acetotartrateboric acidcefmenoximechloramphenicolchlorhexidineciprofloxacinclioquinolfosfomycingentamicinhydrogen peroxidemiconazole show all 17 →
S03AA Antiinfectives 7 drugs
chloramphenicolchlorhexidineciprofloxacingentamicinhexamidineneomycinPolymyxin B

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Trachoma indication 2576002 DOID:11265
Actinomycotic infection indication 11817007 DOID:8478
Gonorrhea indication 15628003 DOID:7551
Infection of skin AND/OR subcutaneous tissue indication 19824006
Gingivostomatitis indication 20607006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Granuloma inguinale indication 28867007 DOID:9113
Acute gonococcal urethritis indication 29864006
Acute gonococcal epididymo-orchitis indication 30168008 DOID:10802
Bronchitis indication 32398004 DOID:6132
Neonatal conjunctivitis indication 34298002 DOID:9699
Sinusitis indication 36971009
Gonorrhea of rectum indication 42746002
Acute gonococcal endometritis indication 65295003 DOID:7527
Urinary tract infectious disease indication 68566005
Yaws indication 70647001 DOID:10371
Gonorrhea of pharynx indication 74372003
Rickettsialpox indication 75096007 DOID:11103
Ornithosis indication 75116005 DOID:11262
Brucellosis indication 75702008 DOID:11077
Syphilis indication 76272004
Acne vulgaris indication 88616000
Bacterial conjunctivitis indication 128350005 DOID:9700
Rocky Mountain spotted fever indication 186772009
Q fever indication 186788009 DOID:11100
Lymphogranuloma venereum indication 186946009 DOID:13819
Pneumonia indication 233604007 DOID:552
Inclusion conjunctivitis indication 266109000
Infective otitis media indication 312218008
Bacterial keratitis indication 314557000
Pharyngitis indication 405737000 DOID:2275
Anthrax indication 409498004 DOID:7427
Relapsing fever indication 420079008 DOID:13034
Chlamydia trachomatis infection of genital structure indication 428015005
Typhus Infections indication
Sexually Transmitted Epididymo-Orchitis indication
Female Urethral Syndrome indication
Rectal Chlamydia Trachomatis Infection indication
Inflammatory Disease of Female Pelvic Organs indication
Superficial Ocular Infection indication
Minor Bacterial Skin Infections indication
Duodenal Ulcer due to H. Pylori indication
Tularemia off-label use 19265001
Enterocolitis off-label use 43752006
Pneumonia due to Mycoplasma pneumoniae off-label use 46970008
Tropical sprue off-label use 47384003 DOID:10607
Plague off-label use 58750007 DOID:3482
Malaria off-label use 61462000 DOID:12365
Blepharoconjunctivitis off-label use 68659002 DOID:2456
Cholangitis off-label use 82403002 DOID:9446
Chlamydial infection off-label use 105629000
Infectious disease of abdomen off-label use 128070006
Ocular rosacea off-label use 200933006
Meibomianitis off-label use 309779001
Infective blepharitis off-label use 312219000
Rosacea off-label use 398909004 DOID:8881
Helicobacter pylori-associated gastritis off-label use 708164002
Chloroquine Resistant Plasmodium Falciparum Malaria off-label use
Alcoholism contraindication 7200002
Lowered convulsive threshold contraindication 19260006
Alcohol intoxication contraindication 25702006
Complete atrioventricular block contraindication 27885002
Shock contraindication 27942005
Hypovolemia contraindication 28560003
Glomerulonephritis contraindication 36171008 DOID:2921
Acute hepatitis contraindication 37871000
Hypokalemia contraindication 43339004
Uremia contraindication 44730006 DOID:4676
Stokes-Adams syndrome contraindication 46935006
Chronic heart failure contraindication 48447003
Atrial fibrillation contraindication 49436004 DOID:0060224
Sinus bradycardia contraindication 49710005
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Decreased respiratory function contraindication 80954004
Disorder of brain contraindication 81308009 DOID:936
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Anemia due to enzyme deficiency contraindication 111577008
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862
Seizure disorder contraindication 128613002
Hypomagnesemia contraindication 190855004
Partial atrioventricular block contraindication 195039008
Non-infective meningitis contraindication 230155003
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Peripheral nerve disease contraindication 302226006
Neutropenic disorder contraindication 303011007 DOID:1227
Hypoxia contraindication 389086002
Pseudomembranous enterocolitis contraindication 397683000
Breastfeeding (mother) contraindication 413712001
Lidocaine Toxicity contraindication
Reduced Hepatic Blood Flow contraindication




🐶 Veterinary Drug Use

SpeciesUseRelation
Cattle Bacterial pneumonia Indication
Cattle Bacterial enteritis caused by Escherichia coli Indication
Cattle Bacterial enteritis caused by Salmonella spp Indication
Cats Bacterial gastroenteritis caused by Escherichia coli Indication
Cats Urinary tract infections caused by Staphylococcus species Indication
Cats Urinary Tract Infections caused by Escherichia coli Indication
Chickens Synovitis caused by Mycoplasma synoviae Indication
Chickens Air sacculitis (air-sac disease chronic respiratory disease) caused by Mycoplasma gallisepticum Indication
Chickens Chronic respiratory disease (CRD or airsac disease) caused by Escherichia coli Indication
Dogs Bacterial gastroenteritis caused by Escherichia coli Indication
Dogs Urinary tract infections caused by Staphylococcus species Indication
Dogs Urinary Tract Infections caused by Escherichia coli Indication
Swine Bacterial enteritis caused by Escherichia coli Indication
Swine Bacterial pneumonia associated with Pasteurella species Indication
Swine Bacterial pneumonia associated with Actinobacillus pleuropneumoniae Indication
Swine Bacterial pneumonia associated with Klebsiella species Indication
Turkeys Control of complicating bacterial organisms associated with bluecomb Indication
Turkeys Infectious synovitis caused by Mycoplasma synoviae Indication

🐶 Veterinary products

ProductApplicantIngredients
Panmycin Tablets Zoetis Inc. 1
Albaplex 3x Tablets, Albaplex Tablets Zoetis Inc. 2
Panmycin 500 Bolus, Panmycin Hydrochloride Zoetis Inc. 1
Panmycin Aquadrops Liquid Zoetis Inc. 1
Tetrachel-Vet Drops, Tetrachel-Vet Syrup Zoetis Inc. 1
Tetrachel-Vet Tablets 100 Zoetis Inc. 1
Tetrachel-Vet Capsules 500 Zoetis Inc. 1
Delta Albaplex 3x Tablets, Delta Albaplex Tablets Zoetis Inc. 3
Albaplex Capsules Zoetis Inc. 2
Tetracycline-Vet Capsules 250 Zoetis Inc. 1
Tetracyn Ointment Zoetis Inc. 1
Tetracycline Soluble Powder Zoetis Inc. 1
Tetracycline Zoetis Inc. 1
Tet-Sol 10, Tet-Sol 324 Huvepharma EOOD 1
Polyotic Huvepharma EOOD 1
Polyotic Oblets Zoetis Inc. 1
Panmycin Capsules Zoetis Inc. 1
Tetra-Sal Zoetis Inc. 1
Polyotic Soluble Powder Concentrate Zoetis Inc. 1
TetraSure 324 Phibro Animal Health Corp. 1
SOLU-TET Zoetis Inc. 1
Tetra-Bac 324 Huvepharma EOOD 1
Tetracycline HCL Powder, Tetracycline Hydrochloride Soluble Powder-324 Quo Vademus LLC 1
Tetrasol Soluble Powder Med-Pharmex Inc. 1
TetraMed 324 HCA Bimeda Animal Health Limited 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.26 acidic
pKa2 7.44 acidic
pKa3 8.06 acidic
pKa4 11.92 acidic
pKa5 12.84 acidic
pKa6 13.45 acidic
pKa7 9.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-synuclein Transporter IC50 5.22 CHEMBL
30S ribosomal protein S4 Ribosomal protein WOMBAT-PK
30S ribosomal protein S9 Ribosomal protein WOMBAT-PK

External reference:

IDSource
4017625 VUID
N0000146005 NUI
D00201 KEGG_DRUG
1336-20-5 SECONDARY_CAS_RN
64-75-5 SECONDARY_CAS_RN
4017625 VANDF
4017626 VANDF
C0039644 UMLSCUI
CHEBI:27902 CHEBI
TAC PDB_CHEM_ID
CHEMBL1440 ChEMBL_ID
CHEMBL1201071 ChEMBL_ID
CHEMBL454950 ChEMBL_ID
D013752 MESH_DESCRIPTOR_UI
DB00759 DRUGBANK_ID
10927 IUPHAR_LIGAND_ID
298 INN_ID
F8VB5M810T UNII
54675776 PUBCHEM_CID
DB09550 DRUGBANK_ID
10395 RXNORM
2048 MMSL
5561 MMSL
6463 MMSL
d00041 MMSL
002738 NDDF
002739 NDDF
002740 NDDF
16355005 SNOMEDCT_US
372809001 SNOMEDCT_US
66261008 SNOMEDCT_US
96075004 SNOMEDCT_US
13930-32-0 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-8505 CAPSULE 250 mg ORAL ANDA 23 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2474 CAPSULE 250 mg ORAL ANDA 23 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2475 CAPSULE 500 mg ORAL ANDA 23 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-590 CAPSULE 500 mg ORAL ANDA 23 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16590-216 CAPSULE 250 mg ORAL ANDA 23 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16590-217 CAPSULE 500 mg ORAL ANDA 23 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-302 CAPSULE 250 mg ORAL ANDA 23 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-640 CAPSULE 500 mg ORAL ANDA 23 sections
tetracycline hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-017 CAPSULE 250 mg ORAL NDA 21 sections
tetracycline hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-018 CAPSULE 500 mg ORAL NDA 21 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-766 CAPSULE 250 mg ORAL ANDA 13 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-766 CAPSULE 250 mg ORAL ANDA 13 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-767 CAPSULE 500 mg ORAL ANDA 13 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-767 CAPSULE 500 mg ORAL ANDA 13 sections
Diabecline HUMAN OTC DRUG LABEL 1 24471-200 OINTMENT 30 mg TOPICAL OTC monograph final 13 sections
TETRA-ABC HUMAN OTC DRUG LABEL 1 43074-103 OINTMENT 0.03 mg TOPICAL OTC monograph final 12 sections
Dyabetex HUMAN OTC DRUG LABEL 1 43074-108 OINTMENT 0.03 mg TOPICAL OTC monograph final 12 sections
Diabecline HUMAN OTC DRUG LABEL 1 43074-112 OINTMENT 30 mg TOPICAL OTC monograph final 13 sections
Tetracycline-ABC HUMAN OTC DRUG LABEL 1 43074-115 OINTMENT 0.03 mg TOPICAL OTC monograph final 12 sections
Acnecycline HUMAN OTC DRUG LABEL 1 43074-116 OINTMENT 0.03 mg TOPICAL OTC monograph final 12 sections
TetraStem HUMAN OTC DRUG LABEL 1 43074-301 OINTMENT 30 mg TOPICAL OTC monograph final 13 sections
Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 3 49884-151 CAPSULE 125 mg ORAL ANDA 27 sections
Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochloride HUMAN PRESCRIPTION DRUG LABEL 3 50742-283 CAPSULE 125 mg ORAL ANDA 20 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51991-906 CAPSULE 250 mg ORAL ANDA 26 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51991-907 CAPSULE 500 mg ORAL ANDA 26 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 52959-336 CAPSULE 500 mg ORAL ANDA 23 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53808-0877 CAPSULE 500 mg ORAL ANDA 22 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-0024 CAPSULE 250 mg ORAL ANDA 23 sections
Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-0025 CAPSULE 500 mg ORAL ANDA 23 sections
Pylera HUMAN PRESCRIPTION DRUG LABEL 3 54868-6151 CAPSULE 125 mg ORAL NDA 27 sections